Literature DB >> 20705559

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Andres Forero-Torres1, Mansoor N Saleh, Janice A Galleshaw, Cheryl F Jones, Jatin J Shah, Ivor J Percent, Lisle M Nabell, John T Carpenter, Carla I Falkson, Helen Krontiras, Marshall M Urist, Kirby I Bland, Jennifer F De Los Santos, Ruby F Meredith, Valerie Caterinicchia, Wanda K Bernreuter, Janis P O'Malley, Yufeng Li, Albert F LoBuglio.   

Abstract

INTRODUCTION: Tumor content or expression of vascular endothelial growth factor (VEGF) is associated with impaired efficacy of antiestrogen adjuvant therapy. We designed a pilot study to assess the feasibility and short-term efficacy of neoadjuvant letrozole and bevacizumab (anti-VEGF) in postmenopausal women with stage II and III estrogen receptor/progesterone receptor-positive breast cancer. PATIENTS AND METHODS: Patients were treated with a neoadjuvant regimen of letrozole orally 2.5 mg/day and bevacizumab intravenously 15 mg/kg every 3 weeks for a total of 24 weeks before the surgical treatment of their breast cancer. Patients were followed for toxicity at 3-week intervals, and tumor assessment (a physical examination and ultrasound) was performed at 6-week intervals. Positron emission tomography (PET) scans were performed before therapy and 6 weeks after the initiation of therapy.
RESULTS: Twenty-five evaluable patients were treated. The regimen was well-tolerated, except in 2 patients who were taken off the study for difficulties controlling their hypertension. An objective clinical response occurred in 17 of 25 patients (68%), including 16% complete responses (CRs) and 52% partial responses. The 4 patients with clinical CRs manifested pathologic CRs in their breasts (16%), although 1 patient had residual tumor cells in her axillary nodes. Eight of 25 patients (32%) attained stage 0 or 1 status. The PET scan response at 6 weeks correlated with clinical CRs and breast pathologic CRs at 24 weeks (P < .0036).
CONCLUSION: Combination neoadjuvant therapy with letrozole and bevacizumab was well-tolerated and resulted in impressive clinical and pathologic responses. The Translational Breast Cancer Research Consortium has an ongoing randomized phase II trial of this regimen in this patient population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705559      PMCID: PMC4451110          DOI: 10.3816/CBC.2010.n.035

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  26 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

Review 2.  Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors.

Authors:  Manish Aghi; E Antonio Chiocca
Journal:  Mol Ther       Date:  2005-08-30       Impact factor: 11.454

3.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

Authors:  Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

4.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

Authors:  R Masood; J Cai; T Zheng; D L Smith; D R Hinton; P S Gill
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

Review 6.  Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions.

Authors:  J Mathew; K S Asgeirsson; K L Cheung; S Chan; A Dahda; J F R Robertson
Journal:  Eur J Surg Oncol       Date:  2008-05-23       Impact factor: 4.424

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

Review 8.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

Authors:  Sonja Loges; Massimiliano Mazzone; Philipp Hohensinner; Peter Carmeliet
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

Authors:  John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum
Journal:  Lancet Oncol       Date:  2008-01       Impact factor: 41.316

10.  Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.

Authors:  R Torrisi; V Bagnardi; A Cardillo; F Bertolini; E Scarano; L Orlando; P Mancuso; A Luini; A Calleri; G Viale; A Goldhirsch; M Colleoni
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

View more
  10 in total

Review 1.  The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.

Authors:  Fangfang Tian; Guohua Shen; Yunfu Deng; Wei Diao; Zhiyun Jia
Journal:  Eur Radiol       Date:  2017-05-05       Impact factor: 5.315

2.  Ultrasound imaging of breast tumor perfusion and neovascular morphology.

Authors:  Kenneth Hoyt; Heidi Umphrey; Mark Lockhart; Michelle Robbin; Andres Forero-Torres
Journal:  Ultrasound Med Biol       Date:  2015-06-24       Impact factor: 2.998

3.  Chemotherapy-resistant metastatic breast cancer.

Authors:  Carrie Marquette; Lisle Nabell
Journal:  Curr Treat Options Oncol       Date:  2012-06

4.  Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Authors:  Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

5.  ¹⁸F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer.

Authors:  Laurence Champion; Florence Lerebours; Pascal Cherel; Veronique Edeline; Anne-Laure Giraudet; Myriam Wartski; Dominique Bellet; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-03       Impact factor: 9.236

Review 6.  Antiangiogenic therapy for breast cancer.

Authors:  Dorte Lisbet Nielsen; Michael Andersson; Jon Lykkegaard Andersen; Claus Kamby
Journal:  Breast Cancer Res       Date:  2010-09-29       Impact factor: 6.466

Review 7.  Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.

Authors:  Antonino Grassadonia; Marta Caporale; Nicola Tinari; Marinella Zilli; Michele DeTursi; Teresa Gamucci; Patrizia Vici; Clara Natoli
Journal:  J Cancer       Date:  2015-05-12       Impact factor: 4.207

8.  A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

Authors:  Teresa Gamucci; Lucia Mentuccia; Clara Natoli; Isabella Sperduti; Alessandra Cassano; Andrea Michelotti; Luigi Di Lauro; Domenico Sergi; Alessandra Fabi; Maria G Sarobba; Paolo Marchetti; Maddalena Barba; Emanuela Magnolfi; Marcello Maugeri-Saccà; Ernesto Rossi; Valentina Sini; Antonino Grassadonia; Domenica Pellegrini; Antonino Astone; Cecilia Nisticò; Franco Angelini; Angela Vaccaro; Arianna Pellegrino; Claudia De Angelis; Michela Palleschi; Luca Moscetti; Ilaria Bertolini; Simonetta Buglioni; Antonio Giordano; Laura Pizzuti; Patrizia Vici
Journal:  J Cell Physiol       Date:  2016-11-30       Impact factor: 6.384

9.  Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.

Authors:  P Sánchez-Rovira; M A Seguí; A Llombart; E Aranda; A Antón; A Sánchez; M Lomas; A Jaén; M Fernández; I Porras; E Dalmau; S Morales; J de la Haba-Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-02-09       Impact factor: 3.405

10.  Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivity.

Authors:  Nadia M Penrod; Casey S Greene; Jason H Moore
Journal:  Genome Med       Date:  2014-04-30       Impact factor: 11.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.